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Inherited molecular defects in nucleotide excision repair genes 
cause the autosomal recessive condition xeroderma pigmento-
sum. Xeroderma pigmentosum is characterized by photo-hyper-
sensitivity of sun-exposed tissues, and by a several thousand-fold 
increase in the risk of developing malignant neoplasms of the skin 
and of the eyes.
Mutations in xeroderma pigmentosum genes that regulate nucle-
otide excision repair, not only predispose persons with xeroderma 
pigmentosum to multiple malignancies, but also promote prema-
ture cutaneous and ocular ageing, and in some cases promote 
progressive neurodegenerative changes.
This paper describes a case of xeroderma pigmentosum with advanced 
cutaneous squamous cell carcinoma, actinic cheilitis and ocular 
lesions in a 19-year old black woman. The extensive ultraviolet radia-
tion-induced skin and eye damage are evidence of neglect of sun-pro-
tection and lack of appropriate medical care from childhood.
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Summary
Introduction
Xeroderma pigmentosum (‘dry pigmented skin’) (XP) 
is a hereditary autosomal recessive disorder character-
ized by mucocutaneous and ocular hypersensitivity to 
UV radiation with irreparable DNA damage and subse-
quent malignant changes; and in some subjects also by 
progressive neurological degeneration [1-6]. The preva-
lence of XP is 1:1,000,000 in the United States and Eu-
rope, and is 1:100,000 in Japan. It is more common in 
populations where marriage of close blood-relatives is 
common. There is no sex or race predilection [1, 2].
Xeroderma pigmentosum occurs in subjects with mo-
lecular defects in the genes involved in nucleotide exci-
sion repair (NER) of ultraviolet-induced DNA lesions 
leading to premature skin and ocular ageing consequent 
upon cellular apoptosis and other UV-induced degen-
erative changes. If sufficient DNA damage occurs, there 
will be cellular transformation and the development of 
malignancies [7-9].
The NER pathway is associated with at least 28 genes, 
some of which are also part of the multi-protein basal 
transcription factor, TFIIH; and some participate in so-
matic growth and development [7]. Mutation in any of 
the NER genes XPA, XPB, XPC, XPD, XPE and XPF 
cause most of XP [2, 10, 11].
Twenty percent of cases of XP are caused by defects in 
the XPV gene encoding an error-prone DNA polymer-
ase pol eta that bypasses unrepaired DNA damage. 
Cells derived from persons with XP owing to XPV 
mutation have a normal NER pathway but have de-
fective DNA replication after UV-induced DNA dam-
age, thus showing deficient DNA translation synthe-
sis [1, 8, 12].
In subjects destined to have XP, fibroblasts and kerati-
nocytes have normal karyotypes without expressing ex-
cessive DNA lesions. However following UV-radiation, 
XP fibroblasts and keratinocytes show a higher level of 
genomic mutations compared to normal cells. It is note-
worthy that subjects with XP have a 10 to 20-fold in-
crease in various internal neoplasms that have no UV 
aetiology compared to the general population [1], sug-
gesting that the repair of endogenous oxidative DNA 
damage may also be dysregulated in some subjects with 
XP [13].
Case report
A 19-year old black female with XP who was under the 
treatment of the Department of Dermatology, School 
of Health Sciences, was referred to the Medunsa Oral 
Health Centre at Ga-Rankuwa, South Africa, for evalu-
ation of a red lesion on the anterior tongue (Fig. 1). She 
had severely damaged facial skin (Figs 1, 2), ‘salt and 
pepper’ pigmentory changes all over her body (Fig. 3) 
and bilateral ocular ulcerations (Fig. 4).
There was no history of other family members having 
XP. The sequence of pathological events in the patient 
were the appearance of irregular hyperpigmentation of 
the skin at 2 years of age, early ocular lesions at 3 years, 
significant visual impairment by 7 years, and the appear-
ance of multiple cancers of the facial skin at the age of 
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17. The patient does not suffer from any neurodegenera-
tive abnormalities or impairment of intelligence.
Until the age of 17 she received neither education re-
garding protection from sun-exposure nor treatment for 
her ocular and skin conditions. When the facial skin can-
cers were diagnosed some were excised.
Many of the lymph nodes of the head and neck were en-
larged. The lesions of the eyelids and conjunctivas were 
probably squamous cell carcinoma (SCC), and there was 
Fig. 1. severe actinic cheilitis of the upper and lower lips and ero-
sions of the anterior one third of the tongue.
Fig. 2. severely damaged facial skin, depigmentation, and scat-
tered exophytic lesions, one on the right cheek, confirmed to be 
squamous cell carcinoma.
Fig. 3. ‘salt and pepper’ pattern of depigmentation/hyperpig-
mentation.
Fig. 4. severe ulcerations of eyelids and conjunctiva.
Fig. 5. large ulcerated squamous cell carcinoma of the right low-
er cheek, photographed 3 months after Figure 2.
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severe corneal scarring. There were no neurological ab-
normalities, and microscopical examination of a biopsy 
specimen of the tip of the tongue showed no evidence of 
epithelial dysplasia.
The patient was supposed to undergo surgical removal 
of the multiple skin SCC and biopsy of the suspicious 
ocular lesions and of the enlarged right sub-mandibular 
lymphnode, but for personal and administrative reasons 
this was delayed.
Three months after our initial examination the facial 
skin malignancies were worse (Figs. 5, 6). Magnetic res-
onance imaging of the head and neck showed associated 
lymphnodes involvement, but there was no infiltration 
of major vessels or metastases to the brain. Because of 
the severity and of the extent of the carcinomatous dis-
ease, the treatment will be palliative.
Molecular events associated  
with nucleotide excision repair  
of UV-induced DNA damage
The nucleotide excision repair (NER) pathway is the 
mechanism responsible for repairing UV-induced he-
lix-distorting lesions of DNA. NER comprises two sub-
pathways, the global genome NER and the transcription-
coupled NER [14-16]. Global genome NER recognises 
and repairs UV-induced DNA lesions in non-transcribed 
DNA throughout the genome, while transcription-cou-
pled NER is initiated by damaged DNA-induced arrest 
of transcribing RNA-polymerase II on the transcribed 
strand of an active gene [10, 13, 15, 16].
The DNA repair pathway of NER is a multi-step mecha-
nism comprising recognition of the UV-induced DNA 
lesion, unwinding of the DNA from around the lesion, 
and finally re-synthesis and ligation [15, 16]. XPC pro-
tein recognises the DNA lesion and recruits TFIIH to the 
DNA-damaged site where XPG protein binds it. XPB and 
XPD helices are two sub-units of TFIIH that open the 
DNA double helix around the lesion. Subsequently XPA 
protein is recruited to the region to stabilize the interme-
diately open repair site, and positions XPF and XPG en-
donucleases, enabling them to excise the damaged strand. 
The cellular replication machinery then fills the remain-
ing gap which is later sealed by ligase [9, 10, 14, 17-20].
The exact rôle of XPE protein in NER activity is un-
known, but it has been suggested that it participates in 
damaged DNA recognition [7, 11, 19]. Thus, subjects 
with XP have molecular defects in cellular DNA repair 
mechanisms because of mutations in one or more NER 
XP genes, leading to hypersensitivity to UV radiation.
This results in the accumulation of unrepaired UV-induced 
DNA damage which either promotes cell death contributing 
to accelerated skin ageing, or promotes cellular transforma-
tion resulting in the development of cancer [9, 16, 17, 19]. 
Persons with XP are at a several thousand-fold increased 
risk of skin cancer compared to healthy subjects [13]; and 
show many features of photo-aging including corneal opac-
ity, atrophy of both the epidermis and the dermis, poikilo-
derma (dyspigmentation) and skin laxity [14].
However, clinical manifestations of XP are not predict-
able according to the type of the XP gene defect: some 
subjects with different molecular defects may manifest 
the same clinical features, while other subjects with the 
same molecular defects may manifest different clinical 
features [7, 14, 16]. 
In addition, genetic polymorphism in XP genes may 
have a functional impact on DNA repair mechanisms 
modifying cancer risk [21]. Epigenetic diversity and 
differences in the stochastic nature of the accumulated 
damaged DNA may contribute to the substantial phe-
notypic variance among persons with XP carrying the 
same causative molecular defect [16]. Although XP 
disorders exhibit phenotypic variability, there are com-
mon denominators to all XP variants (photosensitivity, 
susceptibility to cancer) since the NER mechanism is a 
multistep sequence, and a molecular defect at one step 
dysregulates the function of the downstream steps and 
subsequently of the whole system [7].
Clinical features of Xeroderma 
Pigmentosum
Skin
The hallmark of XP is UV-induced skin hypersensitivity 
manifesting as degenerative and proliferative cutaneous 
changes, including hyperpigmentation, skin atrophy, 
poikiloderma, actinic keratosis, basal cell carcinoma 
(BCC), squamous cell carcinoma (SCC) and melano-
ma [2, 3, 7, 14]. 
About 50% of persons with XP experience acute sun-
burn on minimal exposure to UV radiation and tend to 
develop neurological abnormalities [7].
Cutaneous signs and symptoms usually emerge in children 
under the age of 2 years [1, 3, 7], and up to 60% of persons 
with XP will eventually develop skin cancer [3], in many 
cases with multiple primary lesions [1, 14]. The mean age 
at diagnosis of XP-associated skin cancer is 8 years, 50 
years younger than in the general population [1].
Fig. 6. squamous cell carcinoma on the right cheek showing pro-
gression 3 months after Figure 2.
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Although dark-skinned people have a lower incidence 
of skin cancer compared to light skinned people, most 
probably owing to the photoprotective properties of 
melanin, dark-skinned and light-skinned people with 
XP, have similar incidences of skin cancer emphasizing 
the essential rôle of DNA repair mechanisms even in the 
presence of protection by melanin [2].
Melanin is always thought to be the agent which pro-
vides such protection against UV-induced DNA damage 
as to be responsible for the difference in the incidence of 
premalignant and malignant skin lesions in light skinned 
and dark skinned people. However, the observation that 
dark skinned persons with XP develop carcinomas on 
the pigmented parts of the skin as frequently as light 
skinned persons with XP, brings the importance of the 
protective rôle of melanin into question.
It may well be that when NER mechanisms are intact, 
the levels of UV-induced molecular damage in pigment-
protected dark skin can be effectively repaired so that 
cellular transformation and malignant transformation do 
not occur; but in XP where the NER mechanisms are de-
fective and therefore dysfunctional, the same amount of 
UV penetration of the pigmented skin produces the same 
quantum of UV-induced molecular damage, but in this 
case it is beyond the repair capabilities of the defective 
NER system, and malignancy may ensue.
By contrast, in light skin, the greater penetration of the 
UV in the absence of a heavy pigment layer, can bring 
about molecular damage of an extent that even an intact 
and fully functioning NER system cannot cope and cel-
lular transformation and malignancy will ensue.
Eyes
Between 40% and 80% of persons with XP have ocular 
abnormalities caused by UV-induced DNA alteration to 
epithelial cells of the conjunctiva, the cornea, and the 
eyelid [14, 22]. They also have photophobia, conjunc-
tivitis, keratitis that may lead to corneal opacification, 
hyperpigmentation of the eyelids, loss of eyelashes, and 
malignancies including SCC, basal cell carcinoma and 
melanoma [1-4, 7].
Nervous system
Between 20% and 30% of persons with XP have neurolog-
ical abnormalities [2, 5, 7] which may be mild or severe, 
including loss of fine motor control, ataxia, spasticity, 
rigidity, loss of hearing and progressive mental retarda-
tion [14]. It is presumed that as a consequence of defective 
DNA pathways associated with mutated XP genes, neurons 
accumulate endogenous genotoxic-induced DNA damage, 
and undergo apoptosis leading to loss of neurons [14].
Mouth
Leukoplakia, erythroplakia and SCC of the tip of the 
tongue, actinic cheilitis and SCC of the lips are associ-
ated with XP. The precancerous and cancerous lesions 
of the tip of the tongue, sites seldom affected in the nor-
mal population group, are presumed to be induced by 
UV radiation. This is not a convincing explanation but it 
is the only one offered [1-3, 23].
In the general population, SCC most frequently affects 
the postero-lateral and ventral surfaces of the tongue 
and floor of the mouth of elderly users of tobacco and 
alcohol, and runs an aggressive course. By contrast XP 
associated SCC affects the tip of the tongue of persons 
younger than 20 years of age and runs a slowly progres-
sive course  [2, 3].
Treatment
The treatment of XP is challenging because it is a multi-
organ and multi-system disease, and because usually 
by the time of diagnosis, significant tissue damage has 
already occurred [23]. Malignant tumours may already 
have developed by the third or fourth year of life [24].
Early diagnosis and immediate implementation of rigor-
ous sun-protection measures may prolong the lives of 
persons with XP [7, 23]. About two thirds of unmanaged 
subjects die before the age of 20 years [24], but as re-
ported by Clever and Revet [6], in climates with intense 
sunlight exposure, children with XP who do not imple-
ment sun-protection measures and have limited access 
to modern medical care, have a life expectancy of about 
10 years. 
Persons with XP must avoid exposure to any sources of 
UV light including sunlight, fluorescent, halogen and 
mercury-vapour lights [2], and must wear protective 
clothing and UV-absorbing eye glasses, and must use 
high protection factor sunscreens [1].
XP associated cutaneous, ocular and oral lesions and dis-
orders should be treated as in any other person. Topical 
application of 5-fluorouracil or imiquimod is appropri-
ate for premalignant and surgical excision for malignant 
neoplasms of the skin, tongue, eyelids, conjunctiva and 
cornea. Methyl cellulose or quinodine-containing eye 
drops, and bland ointment at night, constitute correct 
eye-care [1, 3].
It must be remembered that persons with XP who are 
properly protected from sun-light may suffer conse-
quential vitamin D deficiency, and they should routinely 
take vitamin D supplements [2].
Comments
This paper describes a typical case of xeroderma pigmen-
tosum in a young woman of 19 years who had advanced 
SCC of the skin, actinic cheilitis, and ocular lesions such 
that she has been declared legally blind, but she does 
not have neurological abnormalities. Her extensive and 
striking UV-induced skin and eye damage are tragic evi-
dence of the consequences of the lack of sun-protection, 
and of appropriate medical care from an early age. 
Considering the sunny climate where she lives and her 
complete lack of protective measures and the reported 
life expectancy of sufferers from XP living in similar cir-
cumstances, it is remarkable that she has lived so long.
Patients with rare photodermatoses such as xeroderma 
pigmentosum are put at risk by exposure even to sources 
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of low-level ultraviolet radiation (UVR). This risk has 
increased in recent years, with the increased use of high-
intensity discharge light sources such as energy-saving 
fluorescent lamps which emit higher levels of UVR 
and blue light than do low-intensity incandescent light 
sources which emit light towards the yellow/red end of 
the spectrum [25, 26].
Prolonged exposure to high-intensity discharge light-
sources, in particular at short range may constitute a health 
risk not only to photosensitive people, but even to the gen-
eral population [27], making this a public health concern.
There is evidence that exposure to indoor electrical light 
sources, aggrevates photosensitive-related skin con-
ditions including xeroderma pigmentosum and lupus 
erythematosus [27, 28], so photosensitive individuals 
should avoid exposure to high-intensity discharge light 
sources; and should implement light protection meas-
ures even indoors.
References
[1] Rünger TM, DiGiovanna JJ, Kraemer KH. Hereditary disor-
ders of genome instability and DNA repair. In:Wolff K, Gold-
smith LA, Katz SI, et al. Fitzpatrick’s dermatology in general 
medicine. 7th edition. New York: McGraw Hill Co 2008, pp. 
1311-25.
[2] Mahindra P, DiGiovanna JJ, Tamura D, et al. Skin cancers, 
blindness, and anterior tongue mass in African brothers. J Am 
Acad Dermatol 2008;59:881-6.
[3] Goyal JL, Rao VA, Srinivasan R, et al. Oculocutaneous 
manifestations in xeroderma pigmentosa. Br J Ophthalmol 
1994;78:295-7.
[4] Halpern J, Hopping B, Brostoff JM. Photosensitivity, corneal 
scaring and developmental delay: Xeroderma pigmentosum in 
a tropical country. Cases Journal 2008;1:254.
[5] Khan SG, Oh KS, Emmert S, et al. XPC initiation codon muta-
tion in xeroderma pigmentosum in patients with and without 
neurological symptoms. DNA Repair 2009; 8:114-25.
[6] Cleaver JE, Revet I. Clinical implications of the basic defects in 
Cockayne syndrome and xeroderma pigmentosum and the DNA 
lesions responsible for cancer, neurodegeneration and aging. 
Mech Ageing Develop 2008;129:492-7.
[7] Kraemer KH, Patronas NJ, Schiffmann R, et al. Xeroderma 
pigmentosum, trichothiodystrophy and Cockayne syndrome: 
a complex genotype-phenotype relationship. Neuroscience 
2007;145:1388-96.
[8] Liu G, Chen X. DNA polymerase η, the product of the Xeroder-
ma Pigmentosum variant gene and a target of p53, modulates 
the DNA damage checkpoint andp53 activation. Mol Cell Biol 
2006;26:1398-413.
[9] Rademakers S, Volker M, Hoogstraten D, et al. Xeroderma pig-
mentosum group A protein loads as a separate factor onto DNA 
lesions. Mol Cell Biol 2003;23:5755-67.
[10] Yasuda G, Nishi R, Watanabe E, et al. In vivo destabilization 
and functional defects of the xeroderma pigmentosum C pro-
tein caused by a pathogenic missense mutation. Mol Cell Biol 
2007;27:6606-14.
[11] Kulaksiz G, Reardon JT, Sancar A. Xeroderma pigmentosum 
complementation group E protein (XPE/DDB2): purification of 
various complexes of XPE and analyses of their damaged DNA 
binding and putative DNA repair properties. Mol Cell Biol 
2005;25:9784-92.
[12] Inui H, Oh KS, Nadem C, et al. Xeroderma pigmentosum-vari-
ant patients from America, Europe, and Asia. J Investig Derma-
tol 2008;128:2055-68.
[13] Shimizu Y, Shigenori I, Hanaoka F, et al. Xeroderma pigmento-
sum group C protein interacts physically and functionally with 
thymine DNA glycosylase. The EMBO Journal 2003;22:164-73.
[14] Niedernhofer LJ. Tissue-specific accelerated aging in nu-
cleotide excision repair deficiency. Mech Ageing Develop 
2008;129:408-15.
[15] Marini F, Nardo T, Giannattasio M, et al. DNA nucleotide ex-
cision repair-dependent signalling to checkpoint activation. 
PNAS 2006;103:17325-30.
[16] Andressoo JO, Weeda G, de Wit J, et al. An Xpb mouse model 
for combined Xeroderma pigmentosum and Cockayne syndrome 
reveals progeroid features upon further attenuation of DNA re-
pair. Mol Cell Biol 2009;29:1276-90.
[17] Bunick CG, Miller MR, Fuller BE, et al. Biochemical and truc-
tural domain analysis of xeroderma pigmentosum complemen-
tation group C protein. Biochemistry 2006;45:14965-79.
[18] Bernardes de Jesus BM, Bjørås M, Coin F, et al. Dissection of 
the molecular defects caused by pathogenic mutations in the 
DNA repair factor XPC. Mol Cell Biol 2008;28:7225-35.
[19] Stoyanova T, Yoon T, Kopanja D, et al. The xeroderma pigmen-
tosum group E gene product DDB2 activates nucleotide exci-
sion repair by regulating the level of p21Waf1/Cip1. Mol Cell Biol 
2008;28:177-87.
[20] Compe E, Drané P, Laurent C, et al. Dysregulation of the per-
oxisome proliferator-activated receptor target genes by XPD 
mutations. Mol Cell Biol 2005;25:6065-76.
[21] Zhu Y, Yang H, Chen Q, et al. Modulation of DNA damage/
DNA repair capacity by XPC polymorphisms. DNA Repair 
2008;7:141-8.
[22] Gupta B, Anegundi R, Marya CM. Xeroderma pigmentosa; Re-
view and case report. J Oral Health Com Dent 2007;1:43-5.
[23] Neville BW, Damm DD, Allen CM, et al. Dermatologic di-
seases. In: Neville BW, Damm DD, Allen CM, et al., eds. Oral 
and Maxillofacial Pathology. 3rd edition. Missouri: Saunders 
Elsevier 2009, pp. 747-748.
[24] Harper JI. Genetics and genodermatoses. In: Champion RH, 
Burton JL, Burns DA, et al. eds. Rook, Wilkenson, Ebling Text-
book of Dermatology. 6th edition. Oxford: Blackwell Science 
Ltd 1998, pp. 357-436.
[25] Pauley SM. Lighting for the human circadian clock: recent re-
search indicates that lighting has become a public health issue. 
Med Hypoth 2004;63:588-96.
[26] Navara KJ, Nelson RJ. The dark side of light at night: physio-
logical, epidemiological, and ecological consequences. J Pineal 
Res 2007;43:215-24.
[27] Klein RS, Sayre RM, Dowdy JC, et al. The risk of ultraviolet 
radiation exposure from indoor lamps in lupus erythematosus. 
Autoimmun Rev 2009;8:320-4.
[28] Scientific Committee on Emerging and Newly Identified Health 
Risks. Light sensitivity. http://ec.europa.eu/health/ph_risk/risk_
en.htm accessed 16/05/2010.
n Received on February 9, 2010. Accepted on May 18, 2010.
n Correspondence: L. Feller, Box D26, Department of Periodontol-
ogy and Oral Medicine, School of Oral Health Sciences, Faculty 
of Health Sciences, University of Limpopo (Medunsa Campus), 
Medunsa 0204, South Africa - Tel. +012 521 4834 - Fax +012 521 
4835 - E-mail: lfeller@ul.ac.za
